Skyward Specialty Insurance Group (SKWD) has drawn attention after recent trading saw the share price around $42.83, with returns weaker over the past month and the past 3 months compared with the prior 3 years.
See our latest analysis for Skyward Specialty Insurance Group.
For context, the 1 day share price return of a 4.9% decline and the 90 day share price return of a 17.3% decline sit against a 3 year total shareholder return of 120.1%. This suggests that recent momentum has cooled after a strong multi year run.
If this shift has you reassessing your watchlist, it could be a good moment to broaden your search with our screener of 20 top founder-led companies
So with the share price pulling back after a strong multi year run, yet trading at what looks like a steep discount to some value estimates, is Skyward Specialty a reset entry point, or is the market already pricing in future growth?
Most Popular Narrative: 32.6% Undervalued
Skyward Specialty Insurance Group's most followed narrative pegs fair value at $63.50, well above the recent $42.83 close, framing a wide valuation gap for investors to assess.
The company's focus on complex, underserved markets such as small group medical stop loss, innovative property captives, and niche aviation risk enables continued high retention, high margin growth insulated from softening rates in more commoditized lines, underpinning strong earnings quality and sustainable margin expansion.
Want to know what growth path underpins that $63.50 fair value? The narrative leans on compounded top line expansion, firmer margins, and a future earnings multiple that assumes the market keeps rewarding this specialty model.
Result: Fair Value of $63.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on underwriting discipline holding up as competition heats up, and on key MGA partnerships continuing to perform rather than becoming a drag.
Find out about the key risks to this Skyward Specialty Insurance Group narrative.
Another Take On Valuation: Earnings Multiple Check
While the most followed narrative leans on a discounted cash flow style view that points to Skyward Specialty Insurance Group being 32.6% undervalued at $63.50, the current P/E of 11.2x tells a more mixed story compared with peers and an internal fair ratio.
On one hand, 11.2x sits slightly below the US Insurance industry average of 11.4x, which lines up with a modest discount. On the other, it is well above the 6x peer average and below the fair ratio of 15.4x that the market could move toward over time. That spread can look like either a cushion or a warning, depending on how much earnings resilience you are willing to underwrite.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Curious whether the recent pullback is a setback or a fresh opening? Check the data for yourself, act while sentiment is still shifting, and review the 3 key rewards.
Looking for more investment ideas?
If you stop with just one stock, you could miss other opportunities that fit your style, so widen your search now while valuations and stories still vary.
- Target stronger balance sheets by reviewing companies in the solid balance sheet and fundamentals stocks screener (40 results) that combine financial resilience with room for future decisions.
- Spot potential mispricings early by scanning the screener containing 26 high quality undiscovered gems before they attract wider attention.
- Build steadier income potential by checking companies in the 15 dividend fortresses that focus on higher yield payouts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com